Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $274.5 million.

  • Dianthus Therapeutics' Cash from Financing Activities rose 9264087.84% to $274.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $314.9 million, marking a year-over-year increase of 4919.23%. This contributed to the annual value of $255.6 million for FY2024, which is 9137.18% up from last year.
  • As of Q3 2025, Dianthus Therapeutics' Cash from Financing Activities stood at $274.5 million, which was up 9264087.84% from $568000.0 recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Cash from Financing Activities registered a high of $274.5 million during Q3 2025, and its lowest value of -$4.9 million during Q4 2023.
  • Moreover, its 4-year median value for Cash from Financing Activities was $568000.0 (2025), whereas its average is $69.2 million.
  • The largest annual percentage gain for Dianthus Therapeutics' Cash from Financing Activities in the last 5 years was 9264087.84% (2025), contrasted with its biggest fall of 9992.61% (2025).
  • Dianthus Therapeutics' Cash from Financing Activities (Quarter) stood at $96.6 million in 2022, then crashed by 105.03% to -$4.9 million in 2023, then soared by 915.54% to $39.7 million in 2024, then surged by 591.89% to $274.5 million in 2025.
  • Its Cash from Financing Activities stands at $274.5 million for Q3 2025, versus $568000.0 for Q2 2025 and $161000.0 for Q1 2025.